These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 32059703)

  • 21. Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia.
    Kapoor SW; Magambo KA; Kalluvya SE; Fitzgerald DW; Peck RN; Downs JA
    AIDS; 2015 Nov; 29(18):2473-8. PubMed ID: 26372487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis.
    Li Y; Huang X; Chen H; Qin Y; Hou J; Li A; Wu H; Yan X; Chen Y
    BMC Infect Dis; 2020 Jun; 20(1):410. PubMed ID: 32532212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis.
    Rajasingham R; Govender NP; Jordan A; Loyse A; Shroufi A; Denning DW; Meya DB; Chiller TM; Boulware DR
    Lancet Infect Dis; 2022 Dec; 22(12):1748-1755. PubMed ID: 36049486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
    Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
    Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementation of point-of-care testing and prevalence of cryptococcal antigenaemia among patients with advanced HIV disease in Mumbai, India.
    Acharya S; Allam RR; Karanjkar VK; Rathod D; Mahajan R; Deshpande P; Palkar A; Todmal S; Koli S; Dhande S; Dale J; Yeldandi VV; Harshana A; Agarwal R; Upadhyaya S; Nyendak M
    BMJ Open; 2023 Jun; 13(6):e070500. PubMed ID: 37349096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of Advanced HIV Disease, Cryptococcal Antigenemia, and Suboptimal Clinical Outcomes Among Those Enrolled in Care in Vietnam.
    Dat VQ; Lyss S; Dung NTH; Hung LM; Pals SL; Anh HTV; Kinh NV; Bateganya M
    J Acquir Immune Defic Syndr; 2021 Dec; 88(5):487-496. PubMed ID: 34446679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.
    Liechty CA; Solberg P; Were W; Ekwaru JP; Ransom RL; Weidle PJ; Downing R; Coutinho A; Mermin J
    Trop Med Int Health; 2007 Aug; 12(8):929-35. PubMed ID: 17697087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in Uganda.
    Andama AO; den Boon S; Meya D; Cattamanchi A; Worodria W; Davis JL; Walter ND; Yoo SD; Kalema N; Haller B; Huang L;
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):189-94. PubMed ID: 23542636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program.
    Wake RM; Govender NP; Omar T; Nel C; Mazanderani AH; Karat AS; Ismail NA; Tiemessen CT; Jarvis JN; Harrison TS
    Clin Infect Dis; 2020 Apr; 70(8):1683-1690. PubMed ID: 31179488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis.
    Chen J; Zhang R; Shen Y; Liu L; Qi T; Wang Z; Mehraj V; Routy JP; Lu H
    HIV Med; 2019 Jan; 20(1):69-73. PubMed ID: 30311440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of fingerstick cryptococcal antigen lateral flow assay in HIV-infected persons: a diagnostic accuracy study.
    Williams DA; Kiiza T; Kwizera R; Kiggundu R; Velamakanni S; Meya DB; Rhein J; Boulware DR
    Clin Infect Dis; 2015 Aug; 61(3):464-7. PubMed ID: 25838287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITY.
    Vidal JE; Boulware DR
    Rev Inst Med Trop Sao Paulo; 2015 Sep; 57 Suppl 19(Suppl 19):38-45. PubMed ID: 26465368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa.
    Cassim N; Schnippel K; Coetzee LM; Glencross DK
    PLoS One; 2017; 12(2):e0171675. PubMed ID: 28166254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients.
    Wake RM; Britz E; Sriruttan C; Rukasha I; Omar T; Spencer DC; Nel JS; Mashamaite S; Adelekan A; Chiller TM; Jarvis JN; Harrison TS; Govender NP
    Clin Infect Dis; 2018 Feb; 66(5):686-692. PubMed ID: 29028998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementation and Operational Research: Evaluation of a Public-Sector, Provider-Initiated Cryptococcal Antigen Screening and Treatment Program, Western Cape, South Africa.
    Vallabhaneni S; Longley N; Smith M; Smith R; Osler M; Kelly N; Cross A; Boulle A; Meintjes G; Govender NP
    J Acquir Immune Defic Syndr; 2016 Jun; 72(2):e37-e42. PubMed ID: 26926942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter Cryptococcal Antigen Screening of HIV-Infected Patients in Iran.
    Bandalizadeh Z; Shokohi T; Moosazadeh M; Keikha N; Seyedpor H; Rabie Rudsari M; Babamahmoudi F; Ghasemian R; Mardani M; Javanian M; Soleimanpour S; Sefidgar AA; Shokri M; Gouya MM; Seyedmousavi S
    Curr Microbiol; 2020 Aug; 77(8):1667-1672. PubMed ID: 32296917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High prevalence of Cryptococcal antigenemia using a finger-prick lateral flow assay in individuals with advanced HIV disease in Santarém Municipality, Brazilian Amazon Basin.
    Assy JGPL; Said RDC; Pinheiro OC; Brandão ADS; Boulware DR; França FOS; Vidal JE
    Med Mycol; 2021 Sep; 59(9):909-915. PubMed ID: 33908611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventing deaths from cryptococcal meningitis: from bench to bedside.
    Roy M; Chiller T
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):715-7. PubMed ID: 21905781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.
    Parkes-Ratanshi R; Wakeham K; Levin J; Namusoke D; Whitworth J; Coutinho A; Mugisha NK; Grosskurth H; Kamali A; Lalloo DG;
    Lancet Infect Dis; 2011 Dec; 11(12):933-41. PubMed ID: 21982529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for invasive fungal disease using non-culture-based assays among inpatients with advanced HIV disease at a large academic hospital in South Africa.
    van Schalkwyk E; Mhlanga M; Maphanga TG; Mpembe RS; Shillubane A; Iyaloo S; Tsotetsi E; Pieton K; Karstaedt AS; Sahid F; Menezes CN; Tsitsi M; Motau A; Wadula J; Seetharam S; van den Berg E; Sriruttan C; Govender NP
    Mycoses; 2020 May; 63(5):478-487. PubMed ID: 32125004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.